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Atherosclerotic coronary heart disease is the leading cause of morbidity and mortality in industrialized countries, and endothelial 
dysfunction is considered a precursor phenomenon. The nitric oxide produced by the endothelium under the action of endothelial 
nitric oxide synthase has important antiatherogenic functions. Its reduced bioavailabilty is the beginning of the atherosclerotic 
process. The addition of two methyl radicals to arginine, through the action of methyltransferase nuclear proteins, produces asym-
metric dimethylarginine, which competes with L-arginine and promotes a reduction in nitric oxide formation in the vascular wall. 
The asymmetric dimethylarginine, which is itself considered a mediator of the vascular effects of the several risk factors for ath-
erosclerosis, can be eliminated by renal excretion or by the enzymatic action of the dimethylarginine dimethylaminohydrolases. 
Several basic science and clinical research studies suggest that the increase in asymmetric dimethylarginine occurs in the context 
of chronic renal insufficiency, dyslipidemia, high blood pressure, diabetes mellitus, and hyperhomocysteinemy, as well as with 
other conditions. Therapeutic measures to combat atherosclerosis may reverse these asymmetric dimethylarginine effects or at least 
reduce the concentration of this chemical in the blood. Such an effect can be achieved with competitor molecules or by increasing 
the expression or activity of its degradation enzyme. Studies are in development to establish the true role of asymmetric dimethy-
larginine as a marker and mediator of atherosclerosis, with possible therapeutic applications. The main aspects of the formation and 
degradation of asymmetric dimethylarginine and its implication in the atherogenic process will be addressed in this article.
KEYWORDS: Coronary heart disease; Atherogenesis; Endothelium; Nitric oxide; Asymmetric dimethylarginine; Cardiovascular 
risk. 
INTRODUCTION
Atherosclerotic coronary heart disease, which can cause 
an acute occlusion of one or more coronary arteries, is the 
leading cause of morbidity and mortality in industrialized 
countries. Over three million men and women die each 
year due to this disease1 and, according to the World Health 
Organization, it will continue to be the leading cause of 
mortality in the world for the foreseeable future.2
The presence of risk factors for cardiovascular disease, 
mainly in the context of atherosclerotic disease, induces 
changes in the functional as well as in the morphologic 
aspects of the endothelium, readily leading to inflammation, 
thrombosis and vasoconstriction.3 A dysfunctional 
endothelium can be detected by an imbalance between 
dilating and constricting factors, the procoagulant and the 
anticoagulant factors, and the stimulating and inhibiting 
activities related to cellular development and proliferation.4
It becomes necessary to understand the participation of 
the endothelium in the physiopathogenesis of this disease 
using epidemic characteristics. In this review article, we 
will try to summarize the physiological defects of the 
endothelium that are brought on by antagonism of the 
enzyme responsible for the formation of nitric oxide.
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Nitric oxide in vascular homeostasis
The first evidence that the endothelium plays a role in 
vascular tonus control through the production of vasoactive 
substances arose in 1977. 5 Later, in 1980, it was postulated 
that there may exist an endothelium-related relaxing vascular 
factor.6 Subsequently, two independent research groups 
proved that this relaxing factor was nitric oxide (NO).7,8
NO is a free radical that, by definition, is a molecule that 
can exist independently and that features an isolated electron 
in the outermost electron layer.9 It is a small molecule that 
is generated in biological tissues by specific nitric oxide 
synthases (NOS) by way of an oxidative reaction involving 
five electrons.10 This highly reactive molecule performs 
an important oxidative biological signaling role in various 
processes.11 It has a half-life of a few seconds in aqueous 
media, a higher stability in a medium with a low oxygen 
concentration, and is soluble in a lipid-rich environment, 
allowing for quick diffusion within the cytoplasm and 
through plasma membranes.12,13
NO carries out its antiatherogenic effects by stimulating 
the release of soluble guanylate cyclase (GC), producing 
cyclic guanosine monophosphate (cGMP) from cyclic 
guanosine triphosphate (cGTP)5-8 (Figure 1). It originates 
in the endothelium via the conversion of L-arginine to 
L-citrulline in the presence of endothelial NOS (eNOS), 
which is nicotinamide adenine dinucleotide phosphate 
(NADPH)-dependent and requires as cofactors Ca+2/
calmodulin (CaM), flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN) and tetrahydrobiopterin 
(BH4).14
The NO generated by eNOS is important to blood flow 
maintenance because it regulates muscular tone, influences 
the interaction of the white cells and platelets with the 
endothelium and limits the development of neointimal 
hyperplasia by inducing apoptosis of the smooth muscle cells 
of the vessel.15 The inducible isoform of the NOS (iNOS) can 
produce high quantities of NO during inflammation, turning 
it into a cytotoxic agent due to its free radical properties.16 
The neuronal isoform (nNOS) is mainly important for the 
relaxation of the smooth muscle cells, but it also performs a 
role in behavioral inhibition.17
Reduced bioavailability of NO in the vascular wall can be 
a result of diminished expression of eNOS, the absence of its 
substrates or cofactors, or a change in cellular signaling. All 
of these may lead to improper inactivation of the enzyme and 
accelerated degradation of NO by reactive oxygen species 
(ROS) such as oxygen ions, free radicals and peroxides.18
ADMA and endothelial dysfunction
On account of these discoveries, the endothelium was 
accepted by researchers as a paracrine organ.
Biochemists first discovered that methylated arginines 
are excreted in the urine19 and it has since been demonstrated 
that asymmetric dimethylarginine (ADMA) antagonizes 
endothelium-dependent vasodilation, a phenomenon first 
observed in chronic renal failure.20
ADMA is now known to be a mediator molecule of the 
adverse vascular effects of many other factors and markers 
of cardiovascular risk. It is characterized as an amino acid 
of intracellular origin naturally found circulating through 
the plasma, urine, tissues, and cells.20 It is synthesized when 
arginine residues in the nuclear proteins are methylated 
through the action of the protein arginine methyltransferases 
(PRMTs), which are largely distributed throughout the 
human body, through a posttranslational change that adds 
one or two methyl groups to the nitrogens of the guanidine 
incorporated into the proteins21 (Figure 2). There are two 
types of PRMTs, with several isoforms: type 1 catalyzes 
the formation of ADMA, and type 2 catalyzes the formation 
of the symmetric dimethylarginine (SDMA); but both 
enzymes can transfer the methyl radical, producing the NG-
monomethyl-L-arginine (L-NMMA). Of these, only the 
asymmetrically methylated species (ADMA and L-NMMA) 
are inhibitors of NOS; SDMA is not.21
ADMA inhibits the three isoforms of NOS, and is 
equipotent with L-NMMA. It can also uncouple the enzyme, 
generate superoxides, and it interfaces with other targets in 
the cell22. The administration of ADMA in rats causes an 
Figure 1 - Production of NO by endothelial cells. Modified from Davignon 
J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 
2004;109 (suppl III): III27- III32. BH4 = tetrahydrobiopterin.
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increase in the renal vascular resistance and blood pressure,23 
confirming its biological action in vivo. Its levels are much 
higher intracellularly than extracellularly, sufficient in 
some cases to inhibit NOS, as demonstrated with cultivated 
endothelial cells.24 However, an independent additional action 
modality was demonstrated in vivo, in which the chronic 
infusion induced vascular injuries in eNOS knockout mice.25 
Additionally, the three methylarginines interfere with the 
transport of L-arginine as mediated by the cationic amino acid 
carrier within the plasma membrane (y+ channels), explaining 
the SDMA inhibitor effect in the context of NO generation.26
Renal excretion is partly responsible for the elimination 
of methylarginines - SDMA is mainly involved, but ADMA 
and L-NMMA are also extensively metabolized and 
produce citrulline and dimethylamine by the action of the 
dimethylarginine dimethylaminohydrolases (DDAHs).27 
This enzymatic group presents in superior organisms two 
isoforms codified by genes on chromosomes 1 (DDAH-1) 
and 6 (DDAH-2), with distinct tissue-relevant distributions 
but seemingly similar activities.28
The regulation of gene expression and DDAH activity 
remain largely unclear. Incubating endothelial cells with 
tumor necrosis factor–alpha (TNF-alpha) or oxidized low 
density lipoprotein (LDL-ox) decreases the activity of 
this enzyme.29 Other factors, such as the oxidative stress 
associated with S-nitrosylation and high levels of glucose 
and homocysteine, contribute to diminishing DDAH activity, 
leading to an elevation of ADMA levels.30,31
Elevated ADMA in the context of renal insufficiency 
occurs in a variety of ways, probably because the DDAH 
activity can vary under different conditions.32 This molecule 
is dialyzable, but it reaches pathological concentrations after 
dialysis process.33 In the case of chronic renal insufficiency, 
it fulfills the criteria of an uremic toxin because it increases 
in inverse proportion to diminishing renal function. It is a 
guanidine compound, and a product of protein metabolism. 
Multiple biological functions can be impacted by inhibiting 
NOS, including the cardiovascular, osseous, and immune 
systems.20
Subsequent research has also suggested the involvement 
of the liver in the metabolism of dimethylarginines. 
Researchers have demonstrated that hepatocytes abundantly 
express y+ channels in their membranes and contain high 
concentrations of DDAH.34,35 A more recent study carried 
out in patients who underwent hepatic surgery confirmed the 
entrance of ADMA in the liver.36 These and other metabolic 
studies have demonstrated that the liver is essential in 
regulating plasma concentrations of dimethylarginine.
ADMA and cardiovascular risk
Patients with chronic renal insufficiency have an 
increased risk of atherosclerotic vascular disease, and their 
ADMA levels are elevated. In those with end-stage renal 
disease, ADMA has been independently associated with the 
intima-media thickness of the carotid artery and may predict 
its progression during a one-year follow-up period.37 In a 
cohort of hemodialysis patients, scientists found that plasma 
ADMA may be a strong and independent risk factor of total 
mortality and cardiovascular outcome.38
The experimental  atherosclerosis  induced in 
animals such as rabbits39 and monkeys40 on account of a 
hypercholesterolemic diet associates itself with high plasma 
levels of ADMA and endothelial dysfunction. In humans, 
evidence suggests a positive correlation between ADMA 
and cholesterol levels. In a group of hypercholesterolemic 
asymptomatic individuals, the plasma concentration of ADMA 
was almost two-fold higher than in the normocholesterolemic 
individuals of the same age. In associated groups, ADMA 
exhibited a positive association with LDL cholesterol;41 
however, other studies have since failed to show this last 
association.42 As discussed above, LDL oxidation in the 
vascular wall may be responsible for the effect of this 
lipoprotein on ADMA elevation, through inhibition of DDAH 
activity. Accordingly, ADMA may increase the expression of 
oxidized LDL lecithin-like receptor–1 of (LOX-1), the main 
receptor for LDL-ox in endothelial cells.43
The increase in homocysteine can raise the risk of 
atherogenesis by direct inhibition of the activity of DDAH.31 
Figure 2 - Schematic view of the biochemical pathways related to ADMA. 
Modified from Böger RH. Asymmetrical dimethylarginine (ADMA): a novel 
risk marker in cardiovascular medicine and beyond. Annals of Medicine. 
2006;38:126-36.
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On the other hand, we note the arginine methylation 
cycle (Figure 2) - in which the S-adenosylmethionine 
is the methyl donator to the arginine, producing the 
S-adenosylhomocysteine that is ultimately hydrolyzed to 
homocysteine. An excess of this amino acid can contribute to 
cardiovascular risk through an increase in ADMA,31 which is 
considered an important link between hyperhomocysteinemia 
and endothelial dysfunction. Since ADMA contains two 
methyl groups, its synthesis is followed by the generation 
of two homocysteine equivalents. Recently, a moderate but 
highly significant positive association was identified between 
plasma ADMA and homocysteine in a large population 
study.44
The mechanisms of increasing ADMA levels associated 
with diabetes or in the context of insulin resistance are 
not well understood. However, an increase in ADMA 
concentrations has been identified in animal models of type 
1 and 2 diabetes and in patients who suffer from type 2 
diabetes or insulin resistance.45 In diabetic rats, the activity of 
aortic DDAH was significantly reduced and was found to be 
negatively associated with plasma ADMA concentrations.46 
The induction of type 2 diabetes in rats by streptozotocin 
raised plasma ADMA levels, and treatment with insulin 
resulted in its normalization.47
Another study showed that, in the absence of symptoms 
of coronary or peripheral atherosclerotic disease, age, 
median arterial blood pressure, and resistance to insulin 
were core determinants of plasma ADMA concentrations.48 
Another study suggested a positive correlation between 
resistance to insulin and plasma ADMA readings in healthy 
and non-diabetic individuals.49
However, the reports in the literature regarding ADMA 
concentrations in diabetic individuals are inconsistent. 
Poorly-controlled high concentrations were recorded in 
patients suffering from type 2 diabetes,50 although there have 
been reports of diminished levels in similar patient groups.45 
High levels were also reported in gestational diabetes 
mellitus and type 1 diabetes.51
In patients with cardiac insufficiency, ADMA levels are 
high, and this may diminish both ventricular contraction and 
cardiac rates.52 However, it remains unclear whether there 
exists any causative correlation with cardiac or endothelial 
functions. One study suggested that resting cardiac 
output as well as increases in induced-exercise output 
may be energetically attenuated following the infusion of 
ADMA. This suggests a possible role similar to that in the 
physiopathology of cardiac insufficiency and may indicate 
reduced exercise tolerance.52
In reviewing prospective clinical studies, we find strong 
and convincing evidence of the role of ADMA in the 
development of cardiovascular disease. In a Finish case-
control study, high concentrations of ADMA were associated 
with an increased risk of acute coronary events among 
middle-aged and non-smoking men, and especially among 
those with a history of coronary disease.53 In another study 
of patients with stable angina, high plasma concentrations of 
ADMA predicted adverse cardiovascular events following 
percutaneous coronary intervention.54
The multicentric CARDIAC study aimed to evaluate 
the relationship between plasma ADMA levels and 
risk of coronary heart disease.55 This study showed 
that manifestations of cardiovascular diseases, when 
associated with others risk factors such as hypertension, 
hypercholesterolemia, diabetes mellitus and smoking, were 
concomitant with high plasma concentrations of ADMA. 
A concentration of over 1.75 micromoles/liter significantly 
increased the risk, partially supporting the hypothesis that 
ADMA may be a new marker for cardiovascular disease. All 
the aforementioned studies should be evaluated cautiously, 
since they were carried out with specific groups of patients. 
There exist few prospective general population studies that 
have meaningfully established the role of ADMA in the 
hierarchy of both classical risk factors and novel indicators 
of cardiovascular disease.
ADMA diminishes during normal pregnancies, but it 
increases in women with preeclampsia.56 In women with high 
levels of ADMA at the beginning of the pregnancy, a clear 
correlation with endothelial dysfunction has been reported. 
This data only applies to women who subsequently develop 
preeclampsia,57 suggesting that ADMA may be a new risk 
marker for the precocious detection of this complication 
of the gestation cycle. The precise mechanism of ADMA 
elevation in these patients has not been well explained to 
date, but it is thought that changes in renal function may 
explain the observed differences between normal pregnancy 
and preeclampsia groups. Another important observation is 
the involvement of the liver in ADMA processing; hepatic 
dysfunction is a key determinant of plasma ADMA changes 
in pregnant women.
In children with pulmonary hypertension and in 
experimental models of pulmonary hypertension, ADMA 
tends to be high and DDAH is often abnormal.58 In patients 
with idiopathic arterial pulmonary hypertension, ADMA may 
be an independent predictor of mortality.59 Administering 
L-NMMA produces a quick and sustained elevation in 
pulmonary arterial pressure.60
ADMA has a very narrow range of normal concentrations 
within the general population. When these concentrations 
are even only slightly increased, ADMA is associated with 
high cardiovascular risk. Consequently, it is very important 
to achieve high measurement accuracy44. The original 
measurements were taken using HPLC (High Performance 
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Liquid Chromatography), which is still the most common 
method.61 The levels in the plasma of healthy adults vary 
between 0.3 and 1.0 micromole/liter62 and in the spinal fluid 
the corresponding concentrations are between 0.01 and 
0.07 micromole/liter.63 Several methods have been outlined 
using mass spectrometry coupled with a separation system. 
Such measures have more favorable lower detection limits.64 
Antibodies against ADMA are commercially available 
and an ELISA method was recently developed, which can 
recover ADMA from both plasma and serum samples.65
ADMA as a therapeutic option for atherosclerosis
Reversing the effects of increased ADMA or the 
reduction of ADMA levels may be meaningful goals for the 
treatment of endothelial dysfunction. 
Supplementing a patient’s diet with arginine, at least 
theoretically, may efficiently reverse the endothelial 
dysfunction caused by high levels of ADMA. In one 
study, arginine improved endothelial function in patients 
with hypercholesterolemia and increased the achievable 
walking distance of patients with peripheral vascular 
disease.66 In hypercholesterolemic rabbits, the increase in 
the correlation between L-arginine and ADMA explained, at 
least partly, how the formation of NO was accelerated by the 
exogenous administration of L-arginine.67 The basal plasma 
concentration of the L-arginine was almost 25 to 30 times 
higher than the Michaelis-Menten constant (Km) in vitro for 
eNOS. However, exogenous administration of eNOS was 
shown to recover endothelial function in vivo by dampening 
the effects of ADMA elevation, a probable explanation 
for the L-arginine paradox.68 Definitive studies are still 
necessary, with large, randomized and prospective trials that 
may show the therapeutic benefits of that amino acid.
Antagonist drugs of the renin-angiotensin-aldosterone 
system, such as angiotensin-converting enzyme inhibitors 
(ACE inhibitors), angiotensin II receptor blockers, and 
aldosterone antagonists, diminish plasma ADMA levels by 
mechanisms that are unclear. Possible pathways include 
improvements in oxidative stress as impacted by angiotensin 
II, a ROS precursor. Comparing ACE inhibitors both with 
and without antioxidant properties suggests that the former 
may be more effective in reducing ADMA concentrations69. 
Blood pressure reduction per se may also be relevant.
Statins may offer hope for treating endothelial 
dysfunction and elevated ADMA levels. However, almost 
every study to date has failed to support this hypothesis. In 
animals on a hypercholesterolemic diet, lovastatin failed 
to reduce either ADMA or SDMA.70 In rats, administering 
sinvastatin three days prior to LDL failed to alter ADMA 
plasma levels.71
Nevertheless, reports have suggested certain statin effects 
in the context of human ADMA metabolism and rat aortic 
ring control. 72,73 Other studies show that the basal levels 
of ADMA may be impacted by pravastatin in the context 
of endothelial function improvements.74 However, further 
work is required in this realm. The impact of fibrates on 
ADMA levels was initially demonstrated in rats and with 
in vitro studies.75 However, the same effects were not 
observed when in hypertriglyceridemic individuals76 for 
reasons that remain unclear. Niacin also influenced the 
decline of plasma ADMA levels in patients with low HDL 
cholesterol. The mechanism may have involved the depletion 
of S-adenosylmethionine.77 
Ora l  an t id iabe t i cs ,  such  as  met fo rmin  and 
thiazolidinediones, reduce ADMA levels49 by mechanisms 
that are still not sufficiently clear. Thiazolidinediones have 
been shown to influence ADMA release from endothelial 
cells in vitro and ADMA concentrations in rats in vivo.78,79 
A clinical study with this group of drugs clearly showed a 
notable reduction in ADMA levels for both hypertensive and 
non-diabetic individuals. A few studies have also explored 
these drugs with diabetic patients and diabetic animal 
models. Metformin has been shown to reduce ADMA levels 
in type 2 diabetic patients, though this effect may only have 
been a consequence of better glycemic control. We note with 
interest that this drug is structurally similar to ADMA and 
can be transported by y+ channels.80
Among natural compounds with antioxidant properties, 
vitamin E may prevent elevation of ADMA that is induced 
by the administration of LDL in rats81. In humans, this 
same vitamin decreased plasma ADMA in patients with 
chronic renal insufficiency.82 However, to date we have no 
convincing evidence that would support the clinical use of 
this vitamin in human beings.
Estrogens are expected to reduce ADMA levels; however, 
the available clinical evidence remains inconsistent. 
A positive effect was confirmed in placebo-controlled 
clinical studies involving hormone replacement therapy 
with postmenopausal women.83 Another very important 
randomized, placebo-controlled clinical assay carried out in 
healthy post- menopausal women significantly diminished 
plasma ADMA levels, although the L-arginine/ADMA ratio 
did not change. The latter result suggests a neutral effect of 
hormone replacement therapy on ADMA concentrations 
and NO production.84 Most of the evidence in the literature 
suggests no benefit in terms of cardiovascular morbidity or 
mortality.
Other classes of useful drugs in the management of 
cardiovascular disease have been assessed for their effects on 
plasma ADMA levels. Aspirin offers benefits consistent with 
its antioxidant properties.85 Reducing vitamins of plasma 
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homocysteine failed to reduce ADMA levels concomitant 
with their homocysteine-relevant effects.86 Just one clinical 
study has suggested ADMA-relevant effects when folic acid 
is administered to hyperhomocysteinemic individuals.87 
Scientists have reported conflicting results in terms of the 
impact of polysaturated fatty acids on ADMA concentrations. 
The use of recombinant human erythropoietin increases the 
quantity of ADMA and reduces DDAH activity in cultivated 
endothelial cells.88 These data suggest relevant deleterious 
effects on the cardiovascular system - ADMA may be an 
important mediator of such phenomena. We note a recent 
study of interest in which Gomes et al. demonstrated the 
benefit of physical training on ADMA levels in individuals 
with metabolic syndrome.89
CONCLUSION
Recent research has yielded promising new insights into 
endothelial dysfunction in the pathophysiological context 
of atherosclerosis. Nitric oxide is now understood to be of 
great importance in maintaining endothelial integrity. The 
characterization of ADMA as an antagonist molecule of 
L-arginine, the main substrate of NOS, was a very important 
step in understanding early-stage atherosclerotic processes. 
Additional studies, in the realm of both basic science and 
clinical testing, will be necessary understand the role of 
this molecule as a promising marker of future coronary 
events and a possible therapeutic target in the context of 
atherosclerotic vascular disease.
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